According to a market report by Lucintel, the future of the global agoraphobia market looks promising with opportunities in the hospital, clinic, and academic markets. The global agoraphobia market is expected to reach an estimated $2 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are rising rates of panic and anxiety disorders, growing need for patient-centered, individualized treatment for mental health issues, as well as, increasing acceptance of virtual reality exposure treatment.
A more than 150–page report is developed to understand Trends,
opportunity and forecast in agoraphobia market to 2030 by drug treatment
(selective serotonin reuptake inhibitor, norepinephrine reuptake inhibitor,
anti-anxiety medication, and others), therapy (psychotherapy, cognitive
behavioral therapy, exposure therapy, and others), end use (hospital, clinic,
academic, and others), and region (North America, Europe, Asia Pacific, and the
Rest of the World).
In this market, selective serotonin reuptake inhibitor, norepinephrine
reuptake inhibitor, and anti-anxiety medication are the major segments of
agoraphobia market by drug treatment. Lucintel forecasts that selective
serotonin reuptake inhibitor will remain the largest segment over the forecast
period because SSRIs is useful in relieving anxiety associated with agoraphobia,
assisting patients in better managing stressful circumstances.
Within this market, hospital will remain the largest segment.
Download sample by clicking on agoraphobia market.
North America will remain the largest region over the forecast period due
to increase in the frequency of agoraphobia among the region's population.
Eli Lilly and Company, GlaxoSmithKline, Pfizer, AstraZeneca,
Bristol-Myers Squibb Company, Johnson & Johnson, Lundbeck, Takeda
Pharmaceutical, Mylan Pharmaceuticals, and Apotex are the major suppliers in
the agoraphobia market.
This unique research report will enable you to make confident business
decisions in this globally competitive marketplace. For a detailed table of
contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com.
About Lucintel
At Lucintel, we offer solutions for you growth
through game
changer ideas and robust market & unmet
needs analysis. We are based in Dallas, TX and have
been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in
several publications like the Wall Street Journal, ZACKS, and the Financial
Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1 972.636.5056
Explore Our Latest
Publications
Membrane
Structure Market in Canada
Metal forming
Machine Tool Market in Canada
No comments:
Post a Comment